148 related articles for article (PubMed ID: 36460256)
1. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors.
Kreher MA; Konda S; Noland MMB; Longo MI; Valdes-Rodriguez R
J Am Acad Dermatol; 2023 Mar; 88(3):534-542. PubMed ID: 36460256
[TBL] [Abstract][Full Text] [Related]
2. Response to the feasibility of Kreher et al's "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors".
Rypka KJ; Goldfarb N; Mansh M
J Am Acad Dermatol; 2023 Oct; 89(4):e181-e185. PubMed ID: 37379901
[No Abstract] [Full Text] [Related]
3. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids.
Kreher MA; Noland MMB; Konda S; Longo MI; Valdes-Rodriguez R
J Am Acad Dermatol; 2023 Mar; 88(3):521-530. PubMed ID: 36460257
[TBL] [Abstract][Full Text] [Related]
4. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
5. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
6. Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
Nardone B; Orrell KA; Vakharia PP; West DP
Expert Opin Drug Saf; 2018 Feb; 17(2):139-147. PubMed ID: 29103328
[TBL] [Abstract][Full Text] [Related]
7. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
8. Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
Jung JW; Overgaard NH; Burke MT; Isbel N; Frazer IH; Simpson F; Wells JW
Int J Cancer; 2016 Jan; 138(2):281-92. PubMed ID: 25612559
[TBL] [Abstract][Full Text] [Related]
9. A review of heart transplant immunosuppressants and nonmelanoma skin cancer.
Eckembrecher DG; Eckembrecher FJ; Camacho I; Shah H; Dave Y; Patel S; Nouri K
Arch Dermatol Res; 2023 Nov; 315(9):2491-2503. PubMed ID: 37256379
[TBL] [Abstract][Full Text] [Related]
10. The role of new immunosuppressive drugs in nonmelanoma skin cancer in renal transplant recipients.
Bernat-García J; Morales Suárez-Varela M; Vilata-Corell JJ; Marquina-Vila A; Pallardo L; Crespo J
Actas Dermosifiliogr; 2014 Dec; 105(10):940-6. PubMed ID: 25062648
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010.
Mudigonda T; Levender MM; O'Neill JL; West CE; Pearce DJ; Feldman SR
Dermatol Surg; 2013 Mar; 39(3 Pt 1):345-64. PubMed ID: 23190408
[TBL] [Abstract][Full Text] [Related]
12. Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis.
Krzysztofik M; Brzewski P; Cuber P; Kacprzyk A; Kulbat A; Richter K; Wojewoda T; Wysocki WM
Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38276003
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
Gluck M; Hodak E; Davidovici B
Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099
[TBL] [Abstract][Full Text] [Related]
14. Reducing non-melanoma skin cancer risk in renal transplant recipients.
Thet Z; Lam AK; Ranganathan D; Aung SY; Han T; Khoo TK
Nephrology (Carlton); 2021 Nov; 26(11):907-919. PubMed ID: 34240786
[TBL] [Abstract][Full Text] [Related]
15. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
16. Skin cancer in organ transplant recipients--where do we stand today?
Ulrich C; Kanitakis J; Stockfleth E; Euvrard S
Am J Transplant; 2008 Nov; 8(11):2192-8. PubMed ID: 18782290
[TBL] [Abstract][Full Text] [Related]
17. Nonmelanoma skin cancer in inflammatory bowel disease: a review.
Long MD; Kappelman MD; Pipkin CA
Inflamm Bowel Dis; 2011 Jun; 17(6):1423-7. PubMed ID: 21053358
[TBL] [Abstract][Full Text] [Related]
18. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
Wang JL; Yin WJ; Zhou LY; Zhou G; Liu K; Hu C; Zuo XC; Wang YF
Clin Rheumatol; 2020 Mar; 39(3):769-778. PubMed ID: 31823140
[TBL] [Abstract][Full Text] [Related]
19. Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care.
Howard MD; Su JC; Chong AH
Am J Clin Dermatol; 2018 Aug; 19(4):585-597. PubMed ID: 29691768
[TBL] [Abstract][Full Text] [Related]
20. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
